26 September 2016 - The Transparency Commission has published its opinion on Sanofi's GLP-1 analogue.

Lyxumia has a marketing authorization in the treatment of type 2 diabetes in adults to obtain glycemic control in combination with oral antidiabetic agents and/or basal insulin, when these, in addition dietary measures and exercise, have not achieved adequate glycemic control.

The Transparency Commission found that the treatment effect of Lyxumia in terms of glycemic control is modest. Other analogs of GLP-1 have established efficacy in terms of blood glucose control. Lyxumia was not superior to placebo in reducing cardiovascular events. Lyxumia has been given an SMR rating of insufficient.

Read TC opinion for Lyxumia [French]